NASHVILLE, Tenn.--(BUSINESS WIRE)--Published research from a multi-institutional clinical trial shows that physicians frequently use DiaTech Oncology’s customized predictive chemosensitivity test, which is known as the MiCK® assay or CorrectChemo™, when they see an individual patient’s results. The test identifies the most effective chemotherapy drug or drug combination to kill a patient’s specific cancer cells.
